Articles

Why earlier commercial involvement drives smarter strategy

Explore why earlier commercial involvement, adaptive brand planning, and scenario-based decision-making can help life sciences teams respond to market change and strengthen strategy across the asset lifecycle.

Meet Acumetis at AMCP Nexus 2026!

Meet Acumetis at AMCP Nexus 2026 and discover how we help turn evidence into stronger market access strategies.

Direct-to-employer drug models: From niche access model to channel strategy

Discover the market forces driving direct-to-employer adoption and what makes therapies strong candidates for direct commercialization.

12 questions with Kevin Asher

Medical Practice Lead Kevin Asher shares his perspective on Medical Affairs, cross-functional collaboration, navigating industry uncertainty, and the experiences that have shaped his career.

Maik Klasen recognized in Annals of Blood’s 2026 outstanding authors series

Maik Klasen shares his perspective and expertise as part of Annals of Blood’s 2026 Interviews with Outstanding Authors series.

Meet Acumetis at Fierce Pharma week 2026!

Acumetis will be participating in Fierce Pharma Week 2026 in Philadelphia, a large-scale industry event spanning commercialization, marketing, and communications. The event brings together cross-functional leaders to discuss how organizations...

Category dynamics in market access triggered by Most Favored Nation

Learn how Most Favored Nation (MFN) pricing reshapes market access, category dynamics, and global launch strategy through game theory and pricing risk.

The Greek Innovation Fund: a new framework for access to innovative therapies

Learn how Greece's Innovation Fund is advancing earlier access to innovative therapies through a new market access framework.

Demand forecast for plasma collections

Explore how evolving demand for plasma-derived therapies is shaping future plasma collection. Read insights from Acumetis expert Maik Klasen, PhD.